Reuters
17 Jun 2026, 11:43 UTC · 21w ago
Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
Impact · against what's priced in
The partnership between Jazz Pharmaceuticals and AbCellera provides a positive catalyst for both companies by expanding their oncology pipelines. This collaboration introduces new growth potential through the development of T-cell engaging multispecific antibodies.
- ABCL+0.40
No priced-in read yet
- In context
Securing a deal worth up to $876 million provides significant potential revenue and validates AbCellera's platform for multispecific antibody discovery.
Read from the article alone

Search tags




